Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991736 | 0.98 | HRH3 (1.00) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL2283302 | 0.90 | HRH3 (0.86) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL3158896 | 0.90 | HRH3 (0.85) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL12410095 | 0.83 | HRH3 (0.74) | HRH3HRH1S1PR1MAOBMAOA | |
| SCHEMBL12376850 | 0.82 | HRH3 (0.73) | HRH3HRH1MAOBMAOAKCNH2 | |
| SCHEMBL4920804 | 0.82 | HRH3 (0.72) | HRH3HRH1S1PR1MAOBKCNH2 | |
| SCHEMBL2284285 | 0.73 | HRH3 (0.60) | HRH3HRH1S1PR1MAOBKCNH2 | |
| SCHEMBL7809741 | 0.72 | HRH1 (0.56) | HRH3HRH1S1PR1 | |
| SCHEMBL7814084 | 0.72 | HRH1 (0.56) | HRH3HRH1S1PR1 | |
| SCHEMBL12376853 | 0.70 | MAOB (0.58) | HRH3HRH1MAOBKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4251148-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Richter Gedeon Nyrt. (HU) | 2023-10-04 | — | — | EP | claimed |
| WO-2022113008-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | RICHTER GEDEON NYRT. (HU) | 2022-06-02 | — | — | WO | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4251148-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Richter Gedeon Nyrt. (HU) | 2023-10-04 | — | — | EP | disclosed |
| CN-109890817-B | 8- (azetidin-1-yl) - [1,2,4] triazolo [1,5-a ] pyridinyl compounds, compositions, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022113008-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | RICHTER GEDEON NYRT. (HU) | 2022-06-02 | — | — | WO | disclosed |